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Abstract
Transfer of antigen between antigen-presenting cells (APCs) is potentially a physiologically relevant mechanism to spread
antigen to cells with specialized stimulatory functions. Here we show that specific CD8
+ T cell responses induced in
response to intravenous administration of antigen-loaded bone marrow-derived dendritic cells (BM-DCs), were ablated in
mice selectively depleted of endogenous lymphoid-resident langerin
+ CD8a
+ dendritic cells (DCs), suggesting that the
antigen is transferred from the injected cells to resident APCs. In contrast, antigen-specific CD4
+ T cells were primed
predominantly by the injected BM-DCs, with only very weak contribution of resident APCs. Crucially, resident langerin
+
CD8a
+ DCs only contributed to the priming of CD8
+ T cells in the presence of maturation stimuli such as intravenous
injection of TLR ligands, or by loading the BM-DCs with the glycolipid a-galactosylceramide (a-GalCer) to recruit the
adjuvant activity of activated invariant natural killer-like T (iNKT) cells. In fact, injection of a-GalCer-loaded CD1d
2/2 BM-DCs
resulted in potent iNKT cell activation, suggesting that this glycolipid antigen can also be transferred to resident CD1d
+
APCs. While iNKT cell activation per se was independent of langerin
+ CD8a
+ DCs, some iNKT cell-mediated activities were
reduced, notably release of IL-12p70 and transactivation of NK cells. We conclude that both protein and glycolipid antigens
can be exchanged between distinct DC species. These data suggest that the efficacy of DC-based vaccination strategies may
be improved by the incorporation of a systemic maturation signal aimed to engage resident APCs in CD8
+ T cell priming,
and a-GalCer may be particularly well suited to this purpose.
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Introduction
Migratory DCs perform a sentinel role as immature cells in the
peripheral tissues. They respond to local danger signals, such as
factors released by perturbed tissue in response to infection, by
migrating to the draining lymphoid tissues with antigens they have
acquired from the local environment. In the process migratory
DCs undergo maturation, characterized by increased expression of
costimulatory molecules, adhesion molecules and MHC mole-
cules, to provide a stimulatory phenotype capable of driving
activation and proliferation of antigen-specific T cells. There is
also a level of constitutive migration of DCs from peripheral tissues
to the lymphoid organs in the absence of danger, so that sizable
populations of DCs with migratory phenotype can be detected in
lymph nodes and spleen [1]. So-called ‘lymphoid-resident’ DCs
(referred to as resident DCs), on the other hand, seed the lymphoid
tissues directly as precursors released from the bone marrow. In
the steady state, lymphoid-resident DCs represent approximately
half of the DCs in the lymph nodes, and the majority of DCs in the
spleen [1,2]. In mouse spleen three populations of lymphoid-
resident DC can be distinguished on the basis of expression of
CD4 or CD8a (CD4
+ DC, CD8a
+ DC, or double negative DC)
[2,3,4], with some functional specialization between the subsets. In
particular, CD8a
+ DCs have a heightened capacity to cross-
present soluble and cell-associated antigens via MHC class I
molecules to CD8
+ T cells [5,6,7,8], and are major producers of
IL-12 in response to microbial activation stimuli [9,10].
Lymphoid-resident DCs have been generally assumed to acquire
antigensanddanger signalsdirectly fromblood orlymphcirculating
through the lymphoid tissues. A less appreciated mechanism of
acquiring antigen involves transfer from migratory DCs to
lymphoid-resident DCs. It has been shown that migratory DCs
that drain the skin following herpes simplex virus infection can
transfer antigens to lymph node-resident CD8a
+ DCs, which are
then responsible for stimulating CD8
+ T cell responses [11]. A
similar transfer process between migrating DCs and resident
CD8a
+ DCs has been reported in lymph-nodes draining the lung
following influenza infection [12], suggesting antigen transfer is a
physiologically relevant mechanism for spreading antigen to
specialized antigen-presenting cells to enhance specific T cell
responses. The phenotype and maturation status of the recipient
lymphoid-residentDC populations maytherefore be a criticalfactor
in driving effective immune responses. In the case of an infection
such as herpes simplex virus, it is possible that infection-driven
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other situations, effective immunity may be reliant on circulation of
factors capable of triggering maturation of lymphoid-resident DCs.
In the absence of these stimuli, regardless of the maturation state of
the migratory DC, the resident DCs may fail to stimulate immunity,
or could potentially alter the response through, for example, the
induction of T regulatory cells [13]. This possibility may be
particularly relevant in the context of DC vaccination, as transfer of
antigen from injected DCs to endogenous antigen presenting cells
has been reported in animal models [14,15,16], and has been
suggested to contribute significantly to the vaccine induced CD8
+ T
cell responses [17]. Attempts to induce anti-tumor T cell responses
in cancer patients typically involve culture of autologous DCs with
tumor tissue or specific tumor antigens, followed by a DC
maturation step prior to injection. While this maturation step may
enhance migration of the injected DCs from the site of injection to
the draining LN, and enhance T cell priming by ensuring adequate
expression of costimulatory markers, it may not support effective T
cell stimulation by resident DCs that acquire antigen from injected
cells.
We reasoned that CD8
+ T cell activation in response to DC
vaccination could be enhanced by strategies aimed at optimizing
the function of lymphoid-resident DC capable of cross-presenta-
tion. In the mouse, a subset of lymphoid-resident CD8a
+ DC
expressing the c-type lectin langerin (CD207) has been shown to
be primarily responsible for cross-presentation and IL-12 produc-
tion following injection of soluble antigen and adjuvant [18]. We
therefore investigated the role of langerin
+ CD8a
+ DCs after
injection of antigen-loaded DCs in a transgenic animal model in
which langerin
+ cells can be specifically depleted in vivo. We show
that langerin
+ CD8a
+ can indeed capture antigen from intrave-
nously injected DCs, and can significantly contribute to induced
CTL responses, but only if they receive appropriate maturation
stimuli. In this context, loading the injected DCs with a-
galactosylceramide (a-GalCer) to provoke ‘licensing’ by iNKT
cells [19,20,21,22,23,24] proved to be particularly effective, as this
glycolipid antigen was also effectively transferred to resident DCs,
allowing the recipient cells to also become licensed for CTL
induction. Thus, transfer of protein and glycolipid antigens to
lymphoid resident DCs is a feature of DC vaccination that can be
exploited to improve vaccine outcome.
Materials and Methods
Mice
Breeding pairs of the inbred strains C57BL/6j (H2
b, CD45.2
+)
and B6.Sjptprca (H2
b, CD45.1
+) were obtained from the Animal
Resource Centre, Canning Vale, Western Australia. Also used
were B10/Q-H2
q/SgAi mice (H2
q) (referred to as B10.Q),
(Taconic Repository, NIH, Bethesda MD, USA), OT-I mice
expressing a transgenic Va2, Vb5.1/5.2 T cell receptor (TCR)
specific for an H-2K
b-binding peptide of chicken ovalbumin
(OVA257–264) [25], OT-II mice, expressing a transgenic Va2, Vb
5.1/5.2 TCR recognizing the I-A
b-restricted epitope OVA323–339
[26], Langerin-DTREGFP (referred to as lang-DTREGFP) mice
expressing the human Diphtheria toxin (DT) receptor under control
of the langerin promoter [27] (kindly provided by B. Malissen,
Marseille, France), CD1d
2/2 mice [28] (kindly provided by C-R
Wang, University of Chicago, Illinois, USA), which are devoid of
Va14 iNKT cells, and TLR-4
2/2 mice [29] (kindly provided by
Dr S Akira, Hyogo College of Medicine, Japan). For some
adoptive transfer experiments OT-I or OT-II animals were
crossed with B6.Sjptprca animals (referred to as CD45.1/OT-I
and CD45.1/OT-II), so that the congenic marker CD45.1 could
be used to discriminate the transferred cells. All mice were
maintained by the Biomedical Research Unit, Malaghan Institute
of Medical Research, Wellington, New Zealand. Experimental
protocols were approved by Victoria University Animal Ethics
Committee (permit number 2007R17M), and performed accord-
ing to their guidelines. Mice used in this study were 7-10 weeks of
age and, when necessary, matched for age and gender.
Culture media and reagents
Bone marrow-derived DCs (BM-DCs) were cultured in complete
IMDM (cIMDM) consisting of IMDM medium (Invitrogen,
Auckland, New Zealand) supplemented with 5% FBS (Sigma-
Aldrich, Auckland, New Zealand), and 2 mM glutamax, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 50 mM 2-mercaptoethanol
(all Invitrogen). The iNKT cell ligand a-GalCer was manufactured
as described in [30] and solubilized in 150 mM NaCl, 0.5% Tween
20. Endotoxin free chicken OVA was purchased from Profos AG
(Profos AG, Regensburg, Germany). The toll-like receptor (TLR)
ligands used were polyinosinic polycytidylic acid (p(I:C)) (Invivo-
Gen, San Diego, CA, USA) and monophosphoryl lipid A (MPL)
(Sigma-Aldrich). The antibodies used were: anti-Va2 (clone B20.1),
anti-IFN-c (clone XMG1.2), anti-B220 (clone RA3-6B2), anti-
TCR-b (clone H57-597), and anti-Vb5.1/5.2 (clone MR9-4) from
BD-Pharmingen (BD-Pharmingen, Auckland, New Zealand), and
anti-IL-4 (clone 11B11), anti-CD4 (clone 11B11), anti-CD8a (clone
53–6.7), anti-CD86 (clone GL1), and anti-CD45.1 (clone A20) from
eBioscience (eBioscience, San Diego, CA, USA). Propidium iodide
(PI) was from Sigma, CFSE from Molecular Probes (Molecular
Probes, Invitrogen, New Zealand). Diphtheria toxin (DT) was from
Sigma-Aldrich.
Generation, antigen loading, and injection of bone
marrow-derived DCs
Bone marrow-derived dendritic cells (BM-DCs) were generated
by culturing bone-marrow cells from the femur and tibia of 7–10
week old mice in cIMDM media with 10 ng/ml GM-CSF and
20 ng/ml IL-4 in 5 ml of complete medium, with half of the
medium replaced by new medium containing GM-CSF and IL-4
on day 2 and 5. On day 6, cultures were added OVA at 1 mg/ml
and/or a-GalCer at 200 ng/ml. In some cultures OVA was added
with MPL at 100 ng/ml. After overnight incubation, loosely
attached cells were spun down and washed at least three times in
IMDM, and 5610
5 DCs were injected intravenously in 200 ml
IMDM. In some experiments, 25 mg MPL, 100 mg p(I:C), or
200 ng a-GalCer was injected i.v. in the contralateral tail vein after
administration of OVA-loaded BM-DCs.
Flow cytometry
All antibody labeling was performed on ice in FACS buffer (PBS
supplemented with 1% FCS, 0.05% sodium azide, and 2 mM
EDTA). Non-specific FcR-mediated antibody staining was blocked
by incubation for 10 min with anti-CD16/32 Ab (24G2, prepared
in-house from hybridoma supernatant). Flow cytometry was
performed on a BD Biosciences FACSCalibur or BD LSRII
SORP flow cytometer with data analysis using FlowJo software
(Tree Star, Inc., OR, USA).
Tracking of T cell responses
To facilitate detection of OVA-specific T cells, mice received a
cohort of 5610
4 LN cells from CD45.1/OT-I mice or 5610
6 LN
cells from CD45.1/OT-II mice. Mice were tail-bled 7 days after
vaccination and the percentage of OT-I or OT-II cells of all CD8
+
or CD4
+ cells respectively, was determined by flow cytometry. In
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before injection, and the OT-II T cell proliferation was assessed in
the spleen three days after DC vaccination.
In vivo depletion of langerin
+ cells
Lang-DTREGFP mice were injected i.p. with 350 ng of DT 48 h
and 24 h day prior to administration of DCs to deplete langerin
+
cells [18]. In some experiments, control C57BL/6j mice were
similarly injected with DT.
Pentamer staining and in vivo killing assay
Lang-DTREGFP mice were injected with DT or PBS and
vaccinated with C57BL/6j BM-DCs loaded with OVA and a-
GalCer as described above. The percentage of CD8
+ T cells
specific for the OVA257–264-peptide was determined in the blood 6
days later by flow cytometry using anti-CD8 antibody and
fluorescently labeled K
b/OVA257–264 pentamers (ProImmune,
Oxford, UK) according to manufacturers instructions. The
following day, in vivo cytotoxicity was assessed against syngeneic
spleen cell populations loaded with OVA257–264 peptide and
administered by i.v. injection. Mixtures of three populations were
injected: a control population without peptide fluorescence-labeled
with 10 mM of the dye chloromethyl-benzoyl-aminotetramethyl-
rhodamine (CTO) and two target populations loaded with 50 or
5 nM OVA257–264 peptide and fluorescence-labeled with CFSE at
different dye concentrations (1.65 and 0.3 nM respectively).
Peptide-specific lysis was assessed by flow cytometry of blood
16 h later, with the mean percent survival of peptide-loaded
targets cells calculated relative to that of peptide-negative controls.
Cytotoxic activity was expressed as the percent specific lysis,
calculated by the equation 100 - mean percent survival of peptide-
loaded targets.
Intracellular cytokine staining of iNKT cells
Mice were injected i.v. with 5610
5 a-GalCer-loaded BM-DCs.
The mice were sacrificed 2 h later, and single cell suspensions
prepared from spleens were depleted of red blood cells (RBC lysis
buffer, Qiagen), washed twice with cold FACS buffer, and
incubated with anti-Fc receptor antibody 2.4G2 to block non-
specific antibody binding. The cells were then incubated with
CD1d/a-GalCer tetramer (ProImmune) for 20 min on ice followed
by incubation with anti-B220 and anti-TCR-b antibodies for
15 min before being fixed overnight at 4uC in 4% formaldehyde
(Sigma-Aldrich). The cells were then washed twice in saponin buffer
(PBS supplemented with 0.1% BSA, 0.1% saponin, and 0.05%
NaN3 (all Sigma-Aldrich), before incubation with anti-IL-4, anti-
IFN-c, or isotype control antibody, in saponin buffer on ice for
15 min. The cells were finally washed twice in saponin buffer,
resuspended in FACS buffer, and analyzed on a BD FacsCalibur.
For analysis, B220
+ cells were excluded, and iNKT cells gated as
TCR-b
+ CD1d/a-GalCer
+ cells.
Analysis of cytokine release into serum
Blood was collected from the lateral tail vein at different time
intervals after BM-DC administration. Serum was collected after
blood had clotted, and levels of the cytokines IL-12p70, IL-4, and
IFN-c were assessed by bioplex cytokine bead arrays (Bio-Rad)
according to the manufacturer’s instructions.
Uptake of BM-DCs by spleen DCs
BM-DCs generated from B6.Sjptprca (H2
b, CD45.1
+) mice
were labeled with 1.5 mM CFSE, and 10610
6 BM-DCs were
injected i.v. in C57BL/6j mice. Spleens were removed 9–16 h
later, and digested with liberase and DNAse I to aid release of
resident antigen-presenting cells (both Roche, Auckland, New
Zealand). DCs were isolated from the splenocyte preparations with
magnetic sorting (CD11c-MACS MicroBeads, clone N418;
Miltenyi Biotec, Bergisch Gladbach, Germany) according to
manufacturers instructions, and analyzed by flow cytometry with
antibodies against CD11c, CD8a and CD45.2, and using DAPI
(Invitrogen) to discriminate viable cells.
Statistical analyses
A Mann-Whitney test was used to determine statistical
significance in experiments with two experimental groups. In
experiments with three or more groups, statistical significance was
determined using a Krusskal-Wallis test with Dunn’s post test used
to determine statistical significance between two individual groups.
All statistical analyses were done with GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
Resident APCs cross-present antigen acquired from
injected BM-DCs
Vaccination with protein-loaded DCs has been demonstrated to
prime antigen-specific CD4
+ and CD8
+ T cell responses, but the
contribution of resident DCs in this process remains unclear. To
establish whether resident DCs acquire and present antigen derived
from injected DCs, we examined the in vivo priming of a cohort of
OVA-specific CD8
+ transgenic T cells (OT-I T cells) in C57BL/6j
recipients injected with OVA-loaded BM-DCs from syngeneic
(C57BL/6j; H-2
b) or allogeneic (B10.Q; H-2
q) animals. As OT-I T
cells recognize OVA as a processed peptide (OVA257–264) presented
by H-2K
b molecules, only syngeneic BM-DCs can provide a direct
stimulus to these T cells; any OT-I T responses initiated after
injection of allogeneic H-2
q BM-DCs must therefore involve
‘‘indirect’’ cross-presentation via resident APCs. For these exper-
iments, the BM-DCs were also loaded with the iNKT-cell ligand a-
GalCer, which significantly enhances T cell responses by promoting
iNKT cell-mediated licensing of APCs [19,20,21,22,23,24]. To
ensure interaction with iNKT cells, the BM-DCs were administered
i.v., thereby gaining access to the iNKT cell-rich areas of the spleen.
The accumulation of OT-I T cells was determined in the blood 7
days after BM-DC administration (Fig. 1A). As expected, injection
of syngeneic BM-DCs loaded with OVA alone induced a moderate
expansion of the OT-I T cell cohort, while BM-DCs loaded with
both OVA and a-GalCer provoked a much stronger response due
to the adjuvant activity of stimulating iNKT cells (Fig. 1B).
Interestingly, injection of allogeneic BM-DCs loaded with OVA
and a-GalCer also resulted in accumulation of OT-I T cells,
although to lower levels than syngeneic BM-DCs (Fig. 1C), despite
the fact that the allogeneic BM-DCs were unable to directly
stimulate the transgenic T cells. We conclude that antigen can be
transferred from injected DCs to resident APCs for processing and
indirect cross-presentation to CD8
+ T cells.
Depletion of langerin
+ DCs ablates indirect antigen-
presentation by resident DCs
We next determined which population of resident APCs was
responsible for capture and indirect cross-presentation of antigen
derived from injected BM-DCs. Lymphoid-resident DCs express-
ing a homodimer of CD8a have previously been demonstrated to
efficiently cross-present soluble and cell-associated antigens
[5,6,7,8]. In addition, we have recently shown that the ability to
cross-present soluble antigen resides almost exclusively within a
subpopulation of CD8a
+ DCs that express the c-type lectin
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+ CD8a
+
DCs are responsible for cross-presentation of antigen derived from
injected BM-DCs, we took advantage of the lang-DTREGFP mice
[27], in which langerin-expressing DCs, including langerin
+
CD8a
+ DCs, can be selectively depleted by administration of
Diphtheria toxin (DT). We treated lang-DTREGFP or control
C57BL/6j mice with DT prior to vaccination with either
syngeneic or allogeneic BM-DCs loaded with OVA and a-GalCer,
and assessed priming of OT-I T cells as described above.
Depletion of langerin
+ CD8a
+ DCs by DT injection was found
to ablate OT-I T cell priming in response to allogeneic antigen-
loaded BM-DCs, indicating that langerin
+ CD8a
+ DCs mediate
indirect cross-presentation of antigen derived from the injected
cells (Fig. 2A). Interestingly, depletion of langerin
+ CD8a
+ DCs
also reduced priming of OT-I cells in response to syngeneic
antigen-loaded BM-DCs despite these cells being capable of
directly stimulating OT-I T cells (Fig. 2A). In contrast, adminis-
tration of DT had no effect on priming of OT-I T cells in C57BL/
6 mice, demonstrating that this treatment specifically affects T cell
priming by depleting langerin
+ cells (Fig. 2B). Priming of OVA-
specific CD8
+ T cells in the absence of transferred OT-I T cells
was similarly ablated in lang-DTREGFP mice treated with DT and
vaccinated with syngeneic BM-DCs loaded with OVA and a-
GalCer (Fig. 2C). This correlated with a significant impairment in
the ability of DT-treated mice to kill target cells loaded with
OVA257–264-peptide (Fig. 2D). Transfer of antigen to resident
langerin
+ CD8a
+ DCs is therefore a major contributor to CD8
+ T
cell stimulation in this DC vaccination strategy.
Injected antigen-loaded DCs, and not resident DCs,
prime CD4
+ T cell responses
To determine whether transfer of antigen is required to
stimulate CD4
+ T cell responses to injected antigen-loaded BM-
DCs, and to also assess whether langerin
+ CD8a
+ DCs are
involved, we examined priming of a cohort of OVA-specific
transgenic CD4
+ T cells (OT-II cells) in C57BL/6j mice and lang-
DTREGFP mice. Injection of syngeneic BM-DCs loaded with
OVA and a-GalCer resulted in priming of OT-II cells in C57BL/
6j and untreated lang-DTREGFP recipients, with enhanced
accumulation of OT-II cells in the blood at day 7 compared to
non-vaccinated mice (Fig. 3A). However, this response was not
dependent on resident langerin
+ CD8a
+ DCs because prior
depletion of langerin
+ cells in lang-DTREGFP mice had no effect
on the induced response (Fig. 3A). In addition, OT-II T cell
priming was only induced when direct stimulation by the injected
DCs was possible, as no expansion of the OT-II T cell population
was observed in response to antigen-loaded allogeneic BM-DCs
(Fig. 3A). Because the overall OT-II T cell response was low in
these experiments, we performed similar experiments in mice
receiving CFSE-labeled OT-II T cells, and used dilution of the
CFSE dye as a measure of cell division to assess OT-II T cell
activation. Using this more sensitive method, we confirmed the
previous finding that maximal OT-II T cell priming occurred
when the injected BM-DCs were capable of stimulating OT-II T
cells directly (Fig. 3B), although there was some limited T cell
proliferation in response to allogeneic BM-DC which may be
attributed to antigen transfer (Fig. 3B). This latter response was
partially ablated upon depletion of langerin
+ cells (Fig. 3B and C),
although the difference between DT-treated and not-treated mice
did not reach significance (Fig. 3C). In contrast, the larger response
induced to syngeneic BM-DCs was not obviously sensitive to
langerin depletion (Fig. 3B and C). Overall, injected BM-DCs are
primarily responsible for directly stimulating CD4
+ T cells,
whereas a major proportion of the CD8
+ T cell response is
stimulated as a consequence of antigen transfer from injected cells
to resident langerin
+ CD8a
+ DCs.
Resident DCs need a maturation signal to cross-present
antigen acquired from injected BM-DCs
DC maturation is a requirement for optimal stimulation of naı ¨ve
T cells.It isthereforelikelythat residentDCsareinsimilarneed of a
maturation signal in order to stimulate naı ¨ve T cells with antigen
acquired from injected BM-DCs. To address whether this was the
case, we assessed indirect cross-priming of OT-I T cells in C57BL/
6j mice following injection of allogeneic OVA-loaded BM-DCs in
the presence or absence of different adjuvant compounds known to
mature DC. These compounds were injected i.v. at the same time as
the BM-DCs in order to provide systemic access to the lymphoid
Figure 1. Antigen from injected allogeneic BM-DCs is cross-
presented by resident APCs. C57BL/6j mice (CD45.2) were provided
a cohort of OVA-specific CD8
+ T cells from OT-I mice (CD45.1) by
adoptive transfer and were vaccinated 1 d later with BM-DCs derived
from syngeneic mice that had been loaded with OVA 6 a-GalCer in
vitro. Accumulation of OT-I cells was determined in blood 7 d later by
flow cytometry with antibodies specific for CD8 and CD45.1. (A) Flow
cytometry data outlining the gating strategy for the identification of
OT-I T cells, and representative dot plots showing OT-I T cells as a
percentage of all CD8
+ cells in blood on day 7. (B) Pooled data 6 SEM
from three experiments with 4–5 mice per group are shown with each
symbol representing an individual mouse. Statistical significance was
determined using a Kruskal-Wallis test and Dunn’s post test. *p,0.05,
**p,0.01, ***p,0.001 (C) Mice were vaccinated with either syngeneic
(C57BL/6j) or allogeneic (B10.Q) BM-DCs loaded with OVA 6 a-GalCer
and the percentage of OT-I T cells of all CD8
+ cells determined as above.
One representative experiment out of two with 4-5 mice per group is
depicted with SEM.
doi:10.1371/journal.pone.0017657.g001
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direct interactions between the compounds and the injected cells.
Injection of allogeneic OVA-loaded BM-DCs in the presence of the
adjuvant a-GalCer induced significant OT-I T cell priming.
However, this response was almost undetectable in the absence of
a-GalCer (or other maturation signals) (Fig. 4A), suggesting that
resident DCs require an iNKT cell-mediated maturation signal in
order to engage in T cell priming. It was possible that even a limited
amount of binding of a-GalCer to the injected cells in vivo could
make the injected cells susceptible to iNKT cell-mediated lysis,
thereby facilitating the release of antigen available to resident DCs.
In order to rule out this potential contribution to the induced
response, we repeated the above experiment using i.v. injection of
the TLR ligands p(I:C) or MPL as adjuvant compounds, thereby
avoiding the involvement of iNKT cells altogether. Intravenous
administration of each of these TLR ligands also enhanced the
ability of the resident DCs to indirectly cross-present antigen
derived from injected allogeneic BM-DCs (Fig. 4A). The enhance-
Figure 2. Resident langerin
+ CD8a
+ DCs cross-present antigen
derived from injected BM-DCs to CD8
+ T cells. (A) Lang-DTREGFP
mice were injected i.p. with DT to deplete resident langerin
+ cells, or
with PBS vehicle, and then all mice were provided a cohort of
transgenic OT-I T cells (CD45.1) by adoptive transfer. The following day,
the mice were vaccinated i.v. with allogeneic (B10.Q) or syngeneic
(C57BL/6j) BM-DCs loaded with OVA and a-GalCer, and the percentage
of OT-I T cells determined in the blood 7 d later by flow cytometry. One
representative experiment of two with 4-5 mice per group is shown.
The mean percentage 6 SEM is depicted. (B)A si nA, except syngeneic
antigen-loaded BM-DCs were injected into non-transgenic C57BL/6j
mice. One representative experiment out of two with 4 mice per group
is depicted with SEM. (C) Lang-DTREGFP mice were vaccinated with
syngeneic BM-DCs loaded with OVA and a-GalCer as in A but without
the transfer of transgenic OT-I T cells. The percentage of CD8
+ T cells
specific for the OVA257–264 peptide (SIINFEKL) was determined in the
blood six days later by flow cytometry using fluorescently labeled
pentamers of K
b/OVA257–264. Representative dot plots from the
indicated experimental groups are shown. The bar graph shows the
mean percentage + SEM of pentamer positive cells. One experiment
with 4 mice per group is depicted. (D) In vivo cytotoxic activity in mice
from C was determined by measuring the relative recovery of spleen
cells loaded with 50 or 5 nM of OVA257–264 peptide injected i.v. into
vaccinated mice, and collected from blood 17 h later. Statistical
significance was determined with a Mann-Whitney test. *p,0.05.
doi:10.1371/journal.pone.0017657.g002
Figure 3. CD4
+ T cell responses are primed by injected antigen-
loaded BM-DCs with minimal involvement of resident lan-
gerin
+ CD8a
+ DCs. (A) Lang-DTREGFP mice, or C57BL/6j controls, were
injected i.p. with DT or PBS, and were then provided a cohort of OVA-
specific CD4
+ T cells from OT-II mice. The following day, the mice were
vaccinated i.v. with OVA- and a-GalCer-loaded BM-DCs from syngeneic
(C57BL/6j), or allogeneic (B10.Q) mice, and the percentage of OT-II cells
of all CD4
+ cells determined in the blood 7 days later by flow cytometry.
Mean percentages of one representative experiment of two with 5 mice
per group are shown with SEM. (B, C) Lang-DTREGFP mice were treated
with PBS or DT and then provided CFSE-labeled OT-II cells before
vaccination with OVA- and a-GalCer-loaded BM-DCs from syngeneic or
allogeneic mice. (B) Representative histogram plot showing CFSE
dilution of OT-II T cells three days after administration of antigen-
loaded BM-DCs. (C) Mean percentages of divided OT-II T cells with SEM
for one representative experiment of two, with three animals in each
treatment group.
doi:10.1371/journal.pone.0017657.g003
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with DT in lang-DTREGFP recipients, regardless of whether
syngeneic or allogeneic BM-DCs were injected (Fig. 4B), indicating
that MPL enhance CD8
+ T cell priming by maturing the langerin
+
CD8a
+ DCs. It is unlikely that the i.v. administered MPL
contributed to the T cell response by directly stimulating the
injected BM-DCs, as treatment of the OVA-loaded BM-DCs with
MPL in vitro before injection failed to significantly improve the OT-I
response (Fig. 4C). Also, responses to OVA-loaded BM-DCs from
TLR4-deficient mice, which cannot respond directly to MPL, could
be enhanced by i.v. administration of MPL to levels similar to BM-
DCs from TLR4-sufficient mice (Fig. 4D). Overall, these data
suggest that resident langerin
+ CD8a
+ DCs require a maturation
signal to participate in indirect cross-presentation.
Resident antigen-presenting cells present a-GalCer
acquired from injected a-GalCer-loaded BM-DCs
We next examined how loading a-GalCer onto the injected
BM-DCs serves to enhance the stimulatory capacity of resident
CD8
+ langerin
+ DC. The adjuvant effect of a-GalCer-mediated
iNKT cell activation requires that a-GalCer is presented on CD1d
molecules by APCs engaged in T cell stimulation [20,22,31]. This
stimulates iNKT cells to become activated and secrete IL-4 and
IFN-c, and the activated iNKT cells in turn stimulate enhanced
APC function, including secretion of proinflammatory cytokines
such as IL-12 [32,33,34,35,36]. The release of IL-12 then instructs
NK cells to produce more IFN-c [37]. While release of cytokines
into the environment is sufficient to induce up-regulation of
costimulatory molecules such as CD80 and CD86 on local APCs,
the ability of these cells to promote T cell responses is critically
dependent on direct cellular interactions between APC and iNKT
cells, with CD40/CD40L interactions particularly crucial
[20,22,38]. We therefore hypothesized that resident DCs must
acquire a-GalCer from injected DCs in order to interact with
iNKT cells directly. To test this hypothesis, we examined whether
injection of a-GalCer-loaded CD1d-deficient (CD1d
2/2) BM-
DCs, which cannot directly present a-GalCer to iNKT cells, can
activate iNKT cells in C57BL/6j recipients. Similar percentages of
cytokine-positive iNKT cells were induced by a-GalCer-loaded
CD1d
2/2 and wild-type BM-DCs, when intracellular antibody
staining for IFN-c and IL-4 was used as a measure for iNKT cell
activity (Fig. 5A). These data suggest that a-GalCer is transferred
from the injected BM-DC to resident CD1d
+ APCs that can
engage directly in stimulating iNKT cells. We next examined the
role of langerin
+ CD8a
+ DCs in this process by injecting a-
GalCer-loaded CD1d
2/2 BM-DCs into DT-treated or untreated
lang-DTREGFP mice. Similar percentages of activated iNKT cells
(as measured by intracellular cytokine staining) were seen
regardless of DT treatment, indicating that langerin
+ CD8a
+
DCs were dispensable for initial iNKT cell activation (Fig. 5B).
Accordingly, serum levels of IL-4 two hours after administration of
BM-DCs were similar in depleted and non-depleted mice (Fig. 5C).
However, depletion of langerin
+ cells severely reduced the level of
IL-12p70 released into the serum (Fig. 5C), demonstrating an
important role of langerin
+ CD8a
+ DCs in the production of this
cytokine in response to a-GalCer as we have recently reported
[18]. Serum levels of IFN-c were also reduced in recipients
depleted of langerin
+ cells, which is likely to reflect reduced trans-
activation of NK cells as a consequence of lower IL-12 levels
(Fig. 5C). Overall, these data demonstrate that a-GalCer is
transferred from injected BM-DCs to APC populations within the
lymphoid tissue that are capable of stimulating cytokine produc-
tion by iNKT cells. Crucially, the subsequent release of IL-12p70,
which may help in driving cross-primed responses [39], is largely
dependent on the presence of langerin
+ CD8a
+ DCs among the
recipient APCs.
Figure 4. Resident langerin
+ DCs need a maturation signal to
cross-present antigen derived from antigen-loaded BM-DCs.
(A) C57BL/6j mice were provided a cohort of OT-I T cells and vaccinated
i.v. with allogeneic (B10.Q) BM-DCs with or without OVA. The mice were
injected in the contralateral tail vein with either a-GalCer, p(I:C), or MPL
and the percentage of OT-I T cells of all CD8
+ cells was determined in
the blood 7 d later. One representative experiment out of two with 4–5
mice per group is shown with SEM. (B) Lang-DTREGFP mice were
treated with DT, or PBS vehicle, provided a cohort of OT-I T cells, and
then administered OVA-loaded BM-DCs from syngeneic or allogeneic
mice with or without injection of MPL in the contralateral vein. The
percentage of OT-I T cells of all CD8
+ cells was determined in the blood
7 d later. Pooled data from two experiments with 4–5 mice per group is
depicted with SEM. Statistical significance was determined with a
Kruskal-Wallis test and Dunn’s post test. *p,0.05, **p,0.01, NS= not
significant. (C) C57BL/6j mice received a cohort of OT-I T cells as above,
and were vaccinated with syngeneic OVA-loaded BM-DCs that had
been incubated with 100 ng/ml of MPL for 16 h prior to injection, or left
untreated. The mean percentage of OT-I T cells of all CD8
+ cells in the
blood 7 d later is depicted using pooled data from three experiments
with 4–5 mice per group, with SEM. (D) C57BL/6j mice received OT-I T
cells as above and were vaccinated with OVA- and a-GalCer-loaded BM-
DCs derived from C57BL/6j or TLR-4
2/2 mice. The mean percentage of
OT-I T cells of all CD8
+ cells in the blood 7 d later is depicted with SEM
from one representative experiment out of two.
doi:10.1371/journal.pone.0017657.g004
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+ CD8a
+ DCs can acquire cellular
material from injected BM-DCs
The antigen-loaded BM-DCs used in all of the previous
experiments were extensively washed before administration.
Injection of the final washes, or supernatants from cells
subsequently cultured in vitro, was not capable of inducing
proliferation of OT-I cells in vivo, ruling out the possibility that
OVA was ‘leaching’ as free antigen from the cells over time (data
not shown). Some a-GalCer did accumulate in culture superna-
tants, but at levels that were insufficient to account for the in vivo
activities we have observed (data not shown). We therefore
investigated the possibility that the antigens were transferred in an
exchange of cellular material between injected and resident cells.
To determine whether any cellular material could be exchanged in
this manner, BM-DCs derived from CD45.1 congenic mice were
CFSE-labeled and injected into CD45.2
+ C57BL/6j mice, and the
acquisition of CFSE fluorescence by resident (CD45.2
+) DCs
determined 16 h later. Analysis of CD11c
+ cells in the spleens of
recipient animals showed that CFSE fluorescence was acquired by
resident CD8a
+ DCs as well as CD8a
2 DCs (Fig. 6A), with
fluorescence intensity highest in CD8a
+ cells. To establish if CFSE
fluorescence was acquired by the langerin
+ subset, we similarly
injected CFSE-labeled CD45.1 BM-DCs into lang-EGFPDTR
mice. In these mice, all langerin
+ CD8a
+ resident DCs are weakly
GFP positive (Fig. 6B, naı ¨ve). As above, a subset of resident CD8a
+
DCs acquire CFSE fluorescence upon injection of CFSE-labeled
BM-DCs (Fig. 6B, CFSE
+ DC). However, the acquisition of CFSE
fluorescence by resident CD8a
+ DCs is ablated upon prior
depletion of langerin
+ cells by DT (Fig. 6B, CFSE
+ DC + DT, and
Fig. 6C), suggesting cellular material is mainly acquired by CD8a
+
DCs expressing langerin.
Figure 5. Resident APCs acquire a-GalCer from a-GalCer-loaded
BM-DCs in vivo. (A) BM-DCs derived from C57BL/6j (black bars) or
CD1d
2/2 (white bars) mice were loaded with 200 ng/ml of a-GalCer for
16 h and injected i.v. into C57BL/6j mice. The percentage of splenic
iNKT cells expressing intracellular IL-4 or IFN-c was determined 2 h later
by flow cytometry. One representative experiment out of two with
three mice per group is depicted, with SEM. (B) CD1d
2/2 BM-DCs were
incubated with a-GalCer as above and injected into lang-DTREGFP mice,
which had been injected with either PBS (black bars) or DT (white bars).
The percentage of iNKT cells expressing intracellular IL-4 or IFN-c was
determined 2 h later by flow cytometry. One representative experiment
out of two with three mice per group is depicted with SEM. (C) Lang-
DTREGFP mice were treated with PBS (black bars) or DT (white bars) and
then injected i.v. with a-GalCer-loaded BM-DCs from C57BL/6j mice.
Serum concentrations of IL-4, IL-12 p70, and IFN-c were determined 2 h,
5 h, and 10 h later respectively. One representative experiment out of
three with 3-5 mice per group is depicted with SEM.
doi:10.1371/journal.pone.0017657.g005
Figure 6. Injected BM-DCs are taken up by resident DCs. (A)
Pools (n=2) of C57BL/6j mice (CD45.2) were injected with CFSE-labeled
BM-DCs from CD45.1 congenic mice, or left untreated. Spleens were
removed 16 h later and CD11c
+ cells were isolated using magnetic
antibody-coated beads. Depicted dot plots show CFSE fluorescence in
resident (CD45.2
+) CD11c
+ cells. One representative experiment of two
is depicted. (B) CFSE-labeled BM-DCs from CD45.1 congenic mice were
injected into lang-EGFPDTR mice with or without prior depletion of
langerin
+ cells by DT, and the acquisition of CFSE by resident DCs
determined as above. (C) Graphical representation of CFSE acquisition
by resident CD8a
+ and CD8a
2 DCs in lang-DTREGFP mice with or
without prior depletion of langerin
+ cells.
doi:10.1371/journal.pone.0017657.g006
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In this report we investigated the contribution of endogenous
lymphoid-resident DCs to T cell priming after vaccination with
antigen-loaded BM-DCs. We demonstrate that CD8
+ T cells
primed in response to i.v. injection of antigen-loaded BM-DCs can
be primed by a subset of resident DCs expressing CD8a and
langerin. However, this subset of DCs only contributes to T cell
priming if a potent maturation signal is received in combination
with the administered BM-DCs. We also demonstrate that antigen
transfer is not simply limited to protein antigens, as the glycolipid
a-GalCer is also acquired and presented by endogenous DC,
which facilitates licensing of the resident DCs as a consequence of
engaging iNKT cells.
Two models were used to demonstrate that resident DCs
acquire antigen from injected BM-DCs. The first model involved
vaccination with allogeneic OVA-loaded BM-DCs, which were
unable to directly stimulate OVA-specific OT-I T cells, and
therefore required antigen to be transferred to host APCs to
induce expansion of the transgenic T cell population. While this
model showed that OT-I cells could indeed be primed if an
adjuvant was provided, it is possible that this response was inflated
because the allogeneic BM-DCs were lysed by NK cells,
promoting release of antigen to the resident DCs [6]. In order
to avoid this possibility, and characterize the resident DC
population responsible for CD8
+ T cell priming in more detail,
we used a second model in which the recipient DCs were
selectively depleted. Our previous studies have shown that
langerin
+ CD8a
+ DCs in the spleen are critically involved in
cross-presentation of systemic antigens and IL-12 induction [18].
We therefore examined DC vaccination in lang-DTREGFP mice
in which all DCs expressing langerin could be depleted by
injection of DT [27]. Typically, approximately 90% of the splenic
langerin
+ CD8a
+ DC subset is depleted for at least two days in
response to DT (Fig. S1). In contrast, DT injection does not affect
langerin
2 CD8a
+ DCs, CD8a
2 DCs, or the injected DCs
themselves [18]. In addition to being expressed by a subset of
CD8a
+ DCs in the spleen, langerin is expressed by Langerhans
cells in the epidermis, and a subset of dermal and lung DCs
additionally expressing CD103 [27,40,41,42,43]. These DC
subsets may therefore also be depleted by DT administration,
and may be of relevance to the response to injected BM-DCs. BM-
DCs injected i.v. do initially accumulate in much higher numbers
in the lungs compared to the spleen, but then disappear from the
lungs within the first 24 h. In contrast, the number of injected BM-
DCs in the spleen remains high for several days, and the spleen
contains the largest number of injected BM-DCs a day after
injection [44]. Although T cells are likely to be primed in the lung-
draining lymph nodes as well as in the spleen following i.v.
administration of antigen-loaded BM-DCs, the size of the spleen
relative to lymph nodes combined with the continuous presence of
the injected DCs, make the spleen the primary site of T cell
priming [44]. Using the lang-DTREGFP model, depletion of
langerin
+ DCs before i.v. injection of OVA and a-GalCer-loaded
allogeneic BM-DCs completely ablated OT-I T cell priming, and
reduced OT-I T cell priming more than 75% when syngeneic
BM-DCs were used (Fig. 2A). Resident langerin
+ DCs are
therefore responsible for priming the majority of the OVA-specific
CD8
+ T cell response even when syngeneic BM-DCs were used,
and NK-mediated killing of the injected BM-DCs is not required
for antigen transfer.
Lymphoid resident DCs did not prime CD8
+ T cells after
injection of antigen-loaded BM-DCs unless the injected DCs are
administered with a TLR agonist or a-GalCer. As illustrated using
MPL, the adjuvant effect of co-administered TLR ligand was
negated by prior depletion of langerin
+ DCs, suggesting that MPL
enhances CD8
+ T cell priming by inducing maturation of resident
langerin
+ DCs, and not by the stimulation of other cell types, or
the generation of an inflammatory environment. Nor is the effect
of MPL due to maturation of the injected BM-DCs because
responses to TLR-4 deficient BM-DCs were similarly enhanced
when MPL was co-administered. Surprisingly, maturation of BM-
DCs prior to injection had a very limited effect on OT-I T cell
priming despite upregulation of costimulatory markers on the cells
before injection, and induction of release of cytokines such as IL-
12 and IL-6 in vitro (not shown). In fact, our preliminary data
suggest that injected BM-DCs that reach the spleen display a
mature phenotype irrespective of whether they were matured in
vitro prior to injection (data not shown). In contrast to OT-I T
cells, only very few OT-II T cells were primed by allogeneic BM-
DCs loaded with OVA- and a-GalCer, and this response was only
mildly impacted by depletion of langerin
+ DCs. However, OT-II
T cells were efficiently primed by syngeneic BM-DCs loaded with
OVA and a-GalCer, suggesting that it is the injected BM-DCs,
and not lymphoid-resident DCs, that predominate in the
stimulation of naı ¨ve CD4
+ T cells.
The mechanism of antigen transfer in our experiments remains
unclear. It has been shown that membrane fragments can be
exchanged between live DCs following direct cell to cell contact
[45], which may result in transfer of antigens presented on the
surface. Similarly, antigens can be incorporated into exosomes
released from a variety of hematopoietic and non-hematopoietic
cell types (including DCs), and taken up by APCs [46]. Antigen
can also be transferred by the uptake of DCs undergoing
apoptosis, or as apoptotic bodies [14,47]. Our results showed that
splenic APCs acquired fluorescence from injected CFSE-labeled
BM-DCs, suggesting uptake of cellular material. Our experiments
also showed that resident langerin
+ CD8a
+ DCs acquired the most
fluorescence from the CFSE-labeled BM-DCs; some CD8a
2 DCs
acquired fluorescence, but the intensity was lower, suggesting
either less efficient uptake, a qualitatively different mechanism of
uptake, or efficient uptake and subsequent degradation.
It is well-described that the in vivo priming of CD8
+ T cells in
response to intravenous injection of soluble or cell-associated
antigens is critically dependent on CD8a
+ DCs with capacity for
cross-presentation [5,6,7,8]. On the other hand, priming of CD4
+
T cells in response to the same antigen sources is minimally
affected by prior depletion of CD8a
+ DCs, suggesting that other,
CD8a-negative, APCs engage more efficiently in MHC class II
presentation in vivo [18,48]. Inefficient targeting of antigen to
APCs with high propensity for CD4
+ T cell priming could
therefore provide one explanation for the limited CD4
+ T cell
response primed as a consequences of antigen transfer in our
model. It is possible that these differences in APC function can be
explained not just by inherent differences in processing and
presentation capacity, but also by differences in location in the
lymphoid tissue, and capacity to respond to maturation stimuli.
Thus, while it is clear that CD8a
+ DC possess superior cross-
presenting function, the splenic langerin
+ fraction of this subset are
also positioned within the marginal zone [49], and are therefore
well-positioned to acquire antigens from the circulation to divert
into the MHC class I presentation pathway. In fact, langerin
+
CD103
+ CD8a
+ DCs within the marginal zone have been shown
to be particularly efficient at acquiring cellular material [50],
which may be of particular relevance in our DC vaccination
model. The CD8a
+ DC population has also been shown to
produce CCL17 in response to iNKT cell activation, which favors
attraction of naı ¨ve CD8
+ T cells via CCR4 [31], and the langerin
+
Exploiting Endogenous DCs in DC Vaccines
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17657subset responds more quickly to iNKT cell-mediated maturation
stimuli in terms of costimulatory marker upregulation, and CD40
expression, than other DCs of the spleen [18]. Collectively these
factors may favor induction of CD8
+ T cell responses by langerin
+
CD8a
+ DCs, rather than CD4
+ T cell responses, although our
data show that some minimal CD4
+ T cell stimulation attributed
to langerin
+ CD8a
+ DCs may also occur.
Our findings do contrast with previous reports demonstrating MHC
class II presentation as a consequence of antigen transfer from injected
BM-DCs to resident DCs [14,15]. The reason for this discrepancy is
not known, but may reflect the different forms of antigen and
concentration used, particularly the use of high concentrations of an
MHC class II-binding peptide (MCC88–103) in one study where
priming of CD4
+ T cells by endogenous DCs was actually observed
[15]. Alternatively, it has also been shown that OT-II T cells display
low sensitivity to low doses of antigen when compared to OT-I T cells
in vivo [51], which is supported by our studies (Fig. 3, and [18]), and
may explain the negligible CD4
+ T cell response induced as a
consequence of antigen transfer between DCs in our experimental
system. Further experimentation is required to resolve this issue.
Interestingly, vaccination with a-GalCer-loaded CD1d
2/2 BM-
DCs induced iNKT cell activation to similar levels as a-GalCer-
loaded wild-type BM-DCs. As presentation of a-GalCer to iNKT
cells is dependent on CD1d, this finding can only be explained by
transfer of a-GalCer from the injected CD1d-negative BM-DCs to
CD1d-positive resident APCs. Resident DCs may acquire a-
GalCer following phagocytosis of whole antigen-loaded BM-DCs
as previously suggested for the transfer of a-GalCer from loaded
tumor cells to resident DCs [52]. However, despite the proposed
superior ability of CD8a
+ DCs to phagocytose dying cells [6,53],
which is supported by our observations (Fig. 6), the activation of
iNKT cells per se is not dependent on the langerin
+ fraction of this
population, as the depletion of these cells in lang-DTREGFP mice
did not influence initial iNKT cell priming. We cannot rule out the
possibility that other APC subsets such as CD11b
+ CD4
+ splenic
DCs or marginal zone macrophages, can take up cellular material
from antigen-loaded BM-DCs for presentation of a-GalCer. In
this context, subcapsular sinus CD169
+ macrophages were
recently shown to mediate early activation of iNKT cells in lymph
nodes in response to particulate a-GalCer [54].
Although not important for initial iNKT cell activation, a-GalCer-
mediated IL-12 production was critically dependent on resident
langerin
+ CD8a
+ DC, as IL-12 production was severely reduced in
DT treated animals. This is consistent with our previous studies
showing that the absence of langerin
+ cells has no impact on the
ability of injected free a-GalCer to elicit iNKT cells to release IL-4
and IFN-c, but that the subsequent release of large quantities of IL-
12p70 into the serum, which is mediated through interaction of
activated iNKT cells with APCs, is severely impaired [18]. We also
noted in these earlier studies a heightened propensity of langerin
+
CD8a
+ DC to upregulate CD40 in response to free a-GalCer, which
potentially explains the significant role these cells play in driving IL-
12p70 release. The failure to produce IL-12p70 also prevented the
release of large quantities of IFN-c into the serum, which has been
previously described to be secreted by NK cells [37].
Using conditional ablation of langerin
+ cells in lang-DTREGFP
mice, we find that a significant proportion of the CD8
+ T cells
responding to intravenous injection of antigen-loaded BM-DCs are
primed by endogenous langerin
+ DCs. Yet, this subset of DCs only
contributestoT cellprimingifapotentmaturationsignalisreceived
in combination with the administered BM-DCs. As targeting of
antigen to immature DCs in vivo has been shown to induce T cell
tolerance[55,56,57],ourresultsunderscoretheutilityofprovidinga
stimulus for endogenous resident DCs in DC vaccination protocols.
Supporting Information
Figure S1 Splenic CD8
+ langerin
+ DCs are efficiently
depleted by diphtheria toxin injections. F1 crosses of Lang-
DTREGFP x Lang-EGFP were injected i.p. with 350 ng of DT
48 h and 24 h prior to analysis. Single cell suspensions of spleen
cells were generated by Liberase and DNAse treatment as
described in Materials and Methods. Cells were stained with
antibodies against CD11c and CD8 as well as PI for live/dead cell
exclusion. (A) Representative dot plots showing the percentage of
CD11c high cells positive for CD8 and langerin-eGFP in DT
treated or non-treated mice. (B) Percentage of CD8
+ langerin
+
cells of CD11c high cells in individual mice from a total of three
experiments with three mice per group.
(TIF)
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